The study, published in Annals of the Rheumatic Diseases, found that patients receiving Humira for 12 weeks experienced a significant improvement in spine and sacroiliac joint inflammation compared with those who received the placebo. Approximately 36 percent of patients taking Humira reported experiencing at least a 40 percent improvement in pain, compared to 15 percent taking the placebo.
The effects also appeared to have long-term benefits for patients. Nearly one-quarter of the Humira group experienced clinical remission after three months, compare with four percent of the placebo group.
Related Articles on Pain Management:
ASIPP Releases Opioid Guidelines
Study: Pediatric Pain Rehab Boosts Self-Management Skills
PainCare to Open Twelfth Location
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
